Metrion Biosciences has launched the Naᵥ1.9 screening assay, aimed at progressing the discovery along with the development of new pain therapeutics.

Metrion Biosciences 推出了 Naᵥ1.9 筛选分析方法，旨在推动新止痛疗法的发现与开发。

This validated assay is designed to address the challenges associated with Naᵥ1.9 screening and provide decision-ready data for researchers.

该验证过的试验旨在解决与Naᵥ1.9筛选相关的挑战，并为研究人员提供可直接用于决策的数据。

Go deeper with GlobalData

深入探索GlobalData

Reports

报告

Italy Diabetes Care Devices Market Outlook to 2025 - Glucose Monito...

意大利糖尿病护理设备市场展望至2025年 - 血糖监测...

Data Insights

数据洞察

The gold standard of business intelligence.

商业智能的黄金标准。

Find out more

了解更多

Naᵥ1.9 is said to be a voltage-gated sodium channel expressed in peripheral sensory neurons and is a crucial player in the signalling of pain.

Naᵥ1.9 是一种在周围感觉神经元中表达的电压门控钠通道，是疼痛信号传导中的关键角色。

Mutations in this channel can lead to severe pain or insensitivity.

该通道的突变可能导致剧烈疼痛或感觉丧失。

Although Naᵥ1.9 presents an opportunity for non-opioid pain management therapies, research has been hindered by the complexity of stable heterologous expression system development.

尽管Naᵥ1.9为非阿片类疼痛管理治疗提供了机会，但研究因稳定异源表达系统开发的复杂性而受到阻碍。

Metrion noted that the assay enhances its current safety and efficacy screening assay portfolio.

Metrion指出，该检测方法增强了其当前的安全性和有效性筛选检测组合。

GlobalData Strategic Intelligence

全球数据战略情报

US Tariffs are shifting - will you react or anticipate?

美国关税正在变化——你会做出反应还是提前预测？

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

不要让政策变化让你措手不及。通过实时数据和专家分析保持主动性。

By GlobalData

由GlobalData提供

Learn more about Strategic Intelligence

了解有关战略情报的更多信息

It brings new offerings that can expedite and de-risk preclinical programmes, offering insights into Naᵥ1.9 pharmacology.

它带来了可以加速和降低临床前项目风险的新产品，并提供了对Naᵥ1.9药理学的见解。

Designed using a Chinese hamster ovary (CHO) cell line, the assay has been optimised for low variability and high reproducibility.

该检测方法采用中国仓鼠卵巢（CHO）细胞系设计，已经过优化，具有低变异性和高重现性。

It is available with both human-derived and rat-derived clones, which aids in understanding the selectivity of species and developing therapeutics.

它既有人源性克隆，也有大鼠源性克隆，这有助于理解物种选择性并开发治疗方法。

Completing Metrion’s suite of pain-related sodium channel assays, the Naᵥ1.9 assay enables selectivity profiling across channels from Naᵥ1.1 to Naᵥ1.9.

完成了Metrion的疼痛相关钠通道检测套件，Naᵥ1.9检测可实现从Naᵥ1.1到Naᵥ1.9通道的选择性分析。

The company’s offering also includes a range of off-target counter screens, other pain-related ion channel targets, and a comprehensive in vitro proarrhythmia assay (CiPA) panel for evaluating the risk of cardiac safety

公司的产品还涵盖了一系列脱靶反向筛选、其他与疼痛相关的离子通道靶点，以及用于评估心脏安全性风险的全面体外致心律失常检测（CiPA）面板。

Metrion Biosciences’s chief scientific officer Dr Eddy Stevens said: “Metrion is now able to offer a unique combination of sodium channel expertise, high-throughput screening solutions, and research services. These cover the full suite of pain-related sodium channels.

Metrion Biosciences的首席科学官Eddy Stevens博士表示：“Metrion现在能够提供钠通道专业知识、高通量筛选解决方案和研究服务的独特组合。这些涵盖了所有与疼痛相关的钠通道。”

“By facilitating streamlined compound evaluation and accelerated lead optimisation, this service offering has the potential to bring novel pain therapeutics to market rapidly and more cost-effectively.”

“通过促进化合物评估的简化和加速先导化合物的优化，这项服务有可能使新型止痛疗法更快、更经济地进入市场。”